Description
NKTR-255 is an experimental medication currently being studied in clinical trials for certain types of cancer, including colorectal cancer (CRC). It is being investigated in combination with cetuximab, a drug already used to treat CRC. NKTR-255 is designed to work by influencing the body's immune cells, specifically T cells and natural killer (NK) cells, to help them better recognize and attack cancer cells. The goal of the trials is to determine the right dose of NKTR-255 and see if it is safe and effective when used with cetuximab in patients with CRC and other solid tumors. It is important to note that NKTR-255 is still in early-phase clinical trials (Phase 1), meaning its effectiveness and safety profile are still being evaluated.
Mechanism of Action
NKTR-255 is a type of cytokine, which is a signaling molecule that helps regulate the immune system. Specifically, it is designed to modulate the activation and growth of T cells and natural killer (NK) cells. By influencing these immune cells, NKTR-255 aims to enhance their ability to target and destroy cancer cells. The specific details of how it interacts with these cells and the exact pathways involved are still being studied.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.